Evotec (OTCMKTS:EVTCY) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research note issued on Wednesday.
Separately, Zacks Investment Research upgraded shares of Evotec from a “hold” rating to a “buy” rating and set a $52.00 price objective on the stock in a report on Tuesday, December 4th.
EVTCY stock traded up $1.01 during midday trading on Wednesday, hitting $40.84. The company’s stock had a trading volume of 721 shares, compared to its average volume of 720. The company has a quick ratio of 0.90, a current ratio of 0.93 and a debt-to-equity ratio of 0.07. Evotec has a 52-week low of $29.48 and a 52-week high of $52.50. The stock has a market capitalization of $2.92 billion, a PE ratio of 113.44 and a beta of 0.97.
Evotec (OTCMKTS:EVTCY) last announced its quarterly earnings data on Tuesday, November 13th. The company reported $0.34 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.14 by $0.20. Evotec had a net margin of 17.48% and a return on equity of 14.85%. The business had revenue of $111.94 million for the quarter. Analysts expect that Evotec will post 1 EPS for the current fiscal year.
Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services, as well as absorption, distribution, metabolism, excretion, and toxicity services.
Featured Story: What are retained earnings?
To view ValuEngine’s full report, visit ValuEngine’s official website.